- MDVN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $112.1 million.
- MDVN has traded 203,562 shares today.
- MDVN is trading at 2.57 times the normal volume for the stock at this time of day.
- MDVN crossed below its 200-day simple moving average.
'Roof Leaker' stocks are worth watching because trading stocks that begin to experience a breakdown can lead to potentially massive losses. Once psychological and technical resistance barriers like the 200-day moving average are breached on higher than normal relative volume, the stock may then be subject to emotional selling from investors that can continue to drive the stock lower. Regardless of the impetus behind the price and volume action, when a stock moves with weakness and volume it can indicate the start of a new, potentially dangerous, trend. EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDVN with the Ticky from Trade-Ideas. See the FREE profile for MDVN NOW at Trade-Ideas More details on MDVN: Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. MDVN has a PE ratio of 32. Currently there are 11 analysts that rate Medivation a buy, 1 analyst rates it a sell, and 2 rate it a hold.